Verastem Oncology to Present Updated Phase 1/2 Lung Cancer Drug Data at December Conference

0
18
Michael Kauffman, M.D., Ph.D.

BOSTON–Verastem Oncology (Nasdaq: VSTM) announced that updated clinical data from its Phase 1/2 TARGET-D 101 study evaluating VS-7375 in patients with KRAS G12D-mutated metastatic non-small cell lung cancer (NSCLC) will be presented at the IASLC/ASCO 2026 North America Conference on Lung Cancer.

The findings have been selected for a late-breaking oral presentation scheduled for December 5, 2026, during the conference, which takes place December 4-6.

The presentation will focus on patients with previously treated metastatic NSCLC carrying the KRAS G12D mutation, a genetic alteration associated with poorer outcomes in certain lung cancer patients.

Verastem also announced that an abstract describing its ongoing Phase 2 TARGET-D 202 trial has been accepted for a poster presentation. The study is designed to support the potential registration of VS-7375 as a treatment for KRAS G12D-mutated NSCLC.

VS-7375 is an investigational oral, selective KRAS G12D inhibitor designed to target cancer cells driven by mutations in the RAS/MAPK signaling pathway.

The treatment is being developed for patients with cancers carrying the KRAS G12D mutation, for which no specifically targeted therapy has received regulatory approval.

“For people with KRAS G12D-mutated lung cancer, the need for targeted treatment options remains significant. No therapy specifically targeting KRAS G12D is approved, and published research has associated this mutation with worse outcomes, including lower response rates and shorter progression-free survival than other common KRAS variants in metastatic NSCLC,” said Michael G. Kauffman, M.D., Ph.D., President of Development at Verastem Oncology.

“We’re advancing VS-7375, an investigational oral, selective KRAS G12D (ON/OFF) inhibitor with best-in-class potential to enable maximal antitumor efficacy with a favorable tolerability profile. The updated TARGET-D 101 data to be presented at the conference build on the findings we reported in October — including confirmed responses in previously treated NSCLC, with responses observed in patients who had received taxanes. Together, these findings support our broader strategy to move VS-7375 toward the frontline setting.”

The company previously reported confirmed treatment responses in October among patients with KRAS G12D-mutated NSCLC, including individuals who had received taxane-based chemotherapy.

The upcoming presentation is expected to provide updated findings from the Phase 1/2 study as Verastem continues evaluating the drug’s potential effectiveness and safety.

The company’s broader development strategy includes investigating VS-7375 as a possible treatment option for patients earlier in their course of lung cancer therapy.

Verastem Oncology is a biopharmaceutical company focused on developing treatments for cancers driven by the RAS/MAPK signaling pathway.

Leave A Reply

Please enter your comment!
Please enter your name here